H.R.5582 - Abuse Deterrent Access Act of 2018115th Congress (2017-2018) |
|Sponsor:||Rep. Carter, Earl L. "Buddy" [R-GA-1] (Introduced 04/23/2018)|
|Committees:||House - Energy and Commerce; Ways and Means | Senate - Finance|
|Committee Reports:||H. Rept. 115-721|
|Latest Action:||Senate - 06/13/2018 Received in the Senate and Read twice and referred to the Committee on Finance. (All Actions)|
This bill has the status Passed House
Here are the steps for Status of Legislation:
- Passed House
- Passed Senate
- To President
- Became Law
Text: H.R.5582 — 115th Congress (2017-2018)All Information (Except Text)
Text available as:
Referred in Senate (06/13/2018)
Received; read twice and referred to the Committee on Finance
To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.
This Act may be cited at the “Abuse Deterrent Access Act of 2018”.
(a) In general.—Not later than on1e year after the date of the enactment of this Act, the Secretary of Health and Human Services shall conduct a study and submit to Congress a report on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in an MA–PD plan under part C of title XVIII of the Social Security Act or a prescription drug plan under part D of such title of such Act, taking into account any barriers preventing such individuals from accessing such formulations under such MA–PD or part D plans, such as cost-sharing tiers, fail-first requirements, the price of such formulations, and prior authorization requirements.
(b) Definition of abuse-Deterrent opioid formulation.—In this section, the term “abuse-deterrent opioid formulation” means an opioid that is a prodrug or that has certain abuse-deterrent properties, such as physical or chemical barriers, agonist or antagonist combinations, aversion properties, delivery system mechanisms, or other features designed to prevent abuse of such opioid.
Passed the House of Representatives June 12, 2018.
|Attest:||karen l. haas,|